• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Khosla Ventures Acquisition Co. filed SEC Form 8-K: Regulation FD Disclosure

    12/12/23 5:25:01 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KVSA alert in real time by email
    8-K
    false 0001841873 0001841873 2023-08-18 2023-08-18

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

    Date of Report (Date of earliest event reported): August 18, 2023

     

     

    Khosla Ventures Acquisition Co.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-40131   86-1488707

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    2128 Sand Hill Road  
    Menlo Park, California   94025
    (Address of principal executive offices)   (Zip Code)

    (650) 376-8500

    (Registrant’s telephone number, including area code)

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Class A common stock, par value $0.0001 per share   KVSA   The NASDAQ Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 7.01 Regulation FD Disclosure

    Khosla Ventures Acquisition Co. (the “Company”) did not consummate, or execute a letter of intent, agreement in principle or definitive agreement for, an initial business combination on or December 8, 2023, and therefore in accordance with the Company’s certificate of incorporation the Company shall (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not later than December 18, 2023 redeem 100% of the outstanding shares of Class A common stock issued in its initial public offering and not previously redeemed (the “Public Shares”), at a per-share redemption price of $10.75679613, and (iii) as promptly as reasonably possible following such redemption, dissolve and liquidate.

    The Public Shares will be deemed cancelled and will represent only the right to receive the redemption amount. Holders of record of Public Shares of December 8, 2023 will be entitled to receive their pro rata portion of the proceeds of the trust account by delivering their Public Shares to Continental Stock Transfer & Trust Company, the Company’s transfer agent. Beneficial owners of Public Shares held in “street name,” however, will not need to take any action in order to receive the redemption amount.

    The Company’s initial stockholders, including its sponsor and initial directors, have agreed to waive their redemption rights with respect to their outstanding Class B common stock issued prior to the Company’s initial public offering.

    The Company expects that Nasdaq will file a Form 25 with the United States Securities and Exchange Commission (the “Commission”) to delist the Company’s securities. The Company thereafter expects to file a Form 15 with the Commission to terminate the registration of its securities under the Securities Exchange Act of 1934, as amended.

    The information in this Current Report on Form 8-K is being furnished pursuant to Item 7.01 and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise be subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of the filings of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in any such filing.


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        Khosla Ventures Acquisition Co.
    Date: December 12, 2023     By:  

    /s/ Peter Buckland

          Name: Peter Buckland
          Title:   Chief Financial Officer
    Get the next $KVSA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KVSA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KVSA
    SEC Filings

    View All

    SEC Form 15-12G filed by Khosla Ventures Acquisition Co.

    15-12G - Khosla Ventures Acquisition Co. (0001841873) (Filer)

    12/21/23 9:20:51 AM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Khosla Ventures Acquisition Co. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Khosla Ventures Acquisition Co. (0001841873) (Filer)

    12/12/23 5:25:01 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 25-NSE filed by Khosla Ventures Acquisition Co.

    25-NSE - Khosla Ventures Acquisition Co. (0001841873) (Subject)

    12/11/23 5:05:42 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KVSA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Khosla Ventures Acquisition Co. Announces Redemption of Public Shares and Subsequent Dissolution

    MENLO PARK, Calif., Dec. 4, 2023 /PRNewswire/ -- Khosla Ventures Acquisition Co. (the "Company") (NASDAQ:KVSA) today announced that it will redeem all of its outstanding shares of Class A common stock that were issued in its initial public offering and not previously redeemed (the "public shares"), effective as of the close of business on December 11, 2023, as the Company will not consummate an initial business combination on or prior to December 8, 2023. Pursuant to the Amended and Restated Certificate of Incorporation, if the Company does not complete its initial business combination by December 8, 2023, then the Company will: (i) cease all operations except for the purpose of winding up,

    12/4/23 5:38:00 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Valo Health and Khosla Ventures Acquisition Co. Mutually Agree to Terminate Business Combination Agreement

    BOSTON and MENLO PARK, Calif., Nov. 15, 2021 /PRNewswire/ -- Valo Health, LLC ("Valo"), the technology company using human-centric data and artificial intelligence (AI) powered computation to transform the drug discovery and development process and Khosla Ventures Acquisition Co. (NASDAQ:KVSA) ("KVSA"), a special purpose acquisition company sponsored by affiliates of Khosla Ventures, LLC, announced today that both companies have mutually agreed to terminate their previously announced agreement and plan of merger (the "Business Combination Agreement"), effective immediately. Both parties decided to terminate the Business Combination based on current market conditions, particularly in the biot

    11/15/21 5:40:00 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Valo Health and Khosla Ventures Acquisition Co. Announce Additional PIPE Commitments

    BOSTON and MENLO PARK, Calif., Nov. 9, 2021 /PRNewswire/ -- Valo Health, LLC ("Valo"), the technology company using human-centric data and artificial intelligence (AI) powered computation to transform the drug discovery and development process, and Khosla Ventures Acquisition Co. (NASDAQ:KVSA) ("KVSA"), a special purpose acquisition company sponsored by an affiliate of Khosla Ventures, LLC ("Khosla Ventures"), today announced that the private placement of common stock ("PIPE") investment in connection with their previously announced business combination had expanded from $168.5M to over $200M exceeding initial targets.

    11/9/21 4:00:00 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KVSA
    Financials

    Live finance-specific insights

    View All

    Khosla Ventures Acquisition Co. Announces Planned Transfer of Listing to NYSE in Connection with its Proposed Business Combination with Valo Health

    BOSTON and MENLO PARK, Calif., Oct. 28, 2021 /PRNewswire/ -- Khosla Ventures Acquisition Co. (NASDAQ:KVSA) ("KVSA"), a special purpose acquisition company sponsored by an affiliate of Khosla Ventures, LLC ("Khosla Ventures"), today announced that it will voluntarily transfer the listing of its Class A common stock, par value $0.0001 per share ("Class A Common Stock"), from the Nasdaq Capital Market ("Nasdaq") to the New York Stock Exchange ("NYSE") in connection with, and following the closing of, the previously announced business combination (the "Business Combination") with Valo Health, Inc. ("Valo"), the wholly owned subsidiary of Valo Health, LLC ("Valo Health"). The shares of Class A Co

    10/28/21 7:13:00 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KVSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Khosla Ventures Acquisition Co. (Amendment)

    SC 13G/A - Khosla Ventures Acquisition Co. (0001841873) (Subject)

    2/14/24 4:55:28 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Khosla Ventures Acquisition Co. (Amendment)

    SC 13G/A - Khosla Ventures Acquisition Co. (0001841873) (Subject)

    2/12/24 12:56:18 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Khosla Ventures Acquisition Co.

    SC 13G - Khosla Ventures Acquisition Co. (0001841873) (Subject)

    2/14/23 4:18:34 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care